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Abstract
Purpose: Breast cancer is the most common tumour to metastasize to the uveal tract. The mean
survival period after diagnosis of metastasis to the eye, ranges from 10 to 32 months. However,
recent advances in therapy including the use of monoclonal antibody therapy, will hopefully
improve treatment outcomes and prolong survival rates.
Methods: We report a case of a 45 year old woman with a HER2 positive breast cancer, who
developed two metastatic lesions in the left choroid, and the left optic nerve sheath. She underwent
treatment with a combination of chemotherapy (Paclitaxel) and anti-HER2 monoclonal antibodies
(Trastuzumab).
Results: Nine months after treatment, a B-scan showed resolution of the superior choroidal focus,
as well as absence of blood flow within the optic nerve sheath. The inferonasal lesion was still
present but the dimensions were reduced.
Conclusion: The patient underwent a combined treatment of chemotherapy and Trastuzumab to
increase the response rate. Trastuzumab is a humanized monoclonal antibody, which binds to the
extracellular segment of the HER2/neu receptor. Nine months following the therapy her vision was
stable, whilst one focus of the tumour in the affected eye, had regressed. The favourable response
highlights the significant impact of this new therapy, as an alternative to external beam radiotherapy
in patients with ocular metastasis from HER2 (+) breast cancer.
Introduction
Breast cancer is an increasing important health problem
in women, and is the most common tumour to metasta-
size to the uveal tract, presumably due to its large blood
supply. Unfortunately, the mean survival period after
diagnosis of ocular metastasis, ranges from 10 to 32
months [1,2]. However, recent advances in therapy
including monoclonal antibodies (Trastuzumab) with
targeted effects, are likely to improve treatment outcomes
and prolong survival rates.
Published: 4 December 2009
Cases Journal 2009, 2:9143 doi:10.1186/1757-1626-2-9143
Received: 23 September 2009
Accepted: 4 December 2009
This article is available from: http://www.casesjournal.com/content/2/1/9143
© 2009 Papageorgiou et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2009, 2:9143 http://www.casesjournal.com/content/2/1/9143
Page 2 of 3
(page number not for citation purposes)
Case Report
A 45 year old female with a history of metastatic breast
cancer diagnosed in 1995, and treated with mastectomy
and chemotherapy, was referred for an ophthalmological
opinion. She had recently developed deterioration of
vision in the left eye. The patient, 3 months prior to refer-
ral, had undergone treatment with Trastuzumab and Tax-
otere, as well as brain radiotherapy (20 Gy in 5 fractions)
for a solitary metastasis on the right occipital lobe. A series
of subsequent scans had shown almost complete
response.
At presentation, the visual acuity on the left eye was 6/9
with head posture and there was a left RAPD. Fundoscopy
showed a white choroidal lesion with central hyper pig-
mentation, inferonasal and adjacent to the left optic
nerve. In addition, there was optic disc pallor. A visual
field test showed a left superior altitudinal defect. Fluores-
cein angiography showed early hyperflourescence with
central masking that was highly suggestive of metastatic
involvement of the choroid (Fig 1). A B-scan was per-
formed, showing two elevated lesions superior (Fig 2) and
inferonasal (3.3 mm transverse, 2.8 mm longitudinal base
and 1.0 mm elevation) to the optic disc. In addition blood
flow was detected in the optic nerve sheath, suggesting
tumour extension to the optic nerve.
The patient was commenced on Paclitaxel and Trastuzu-
mab at four weekly intervals, and was responding well
with very little systemic toxicity. Nine months later her
visual acuity on the left eye was 6/9 without the head pos-
ture with persistence of the left visual field defect. A sub-
sequent B-scan showed complete resolution of the
superior focus, as well as absence of blood flow within the
optic nerve sheath. The inferonasal lesion (Fig 3) was still
present but the dimensions were reduced (3.5 mm trans-
verse, 2.3 mm longitudinal base and 0.6 mm elevation).
Enhanced scans were performed and showed absence of
metastatic disease, whilst a bone scan showed significant
reduction of isotope uptake. The patient is currently on
Trastuzumab three weekly and under combined follow
up.
Discussion
The incidence of ocular metastasis from breast cancer
ranges from 9% to 37%. It also accounts for 39% to 49%
Fluorescein angiography of the left eye showing early hyper- flourescence with central masking inferonasal to the optic  disc Figure 1
Fluorescein angiography of the left eye showing early 
hyperflourescence with central masking inferonasal 
to the optic disc.
B-scan of the left eye before treatment showing the superior  lesion (4.4 mm transverse base, 3.9 mm longitudinal base and  1.0 mm elevation) Figure 2
B-scan of the left eye before treatment showing the 
superior lesion (4.4 mm transverse base, 3.9 mm lon-
gitudinal base and 1.0 mm elevation).
B-scan 8 months post-treatment showing the reduced  dimensions of the inferonasal lesion (3.5 mm transverse, 2.3  mm longitudinal base and 0.6 mm elevation) Figure 3
B-scan 8 months post-treatment showing the 
reduced dimensions of the inferonasal lesion (3.5 mm 
transverse, 2.3 mm longitudinal base and 0.6 mm ele-
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of all uveal metastases. There are few reports about the
response of choroidal metastases to chemotherapy and
radiotherapy. A recent study at the Oncology service of
Wills Eye Hospital reported that the average survival time
after the diagnosis of ocular metastasis was 65% at 1 year
and 24% at 5 years. However, survival rates depend on
general health, early diagnosis and advances in therapy
[2,3].
Trastuzumab, is a humanized monoclonal antibody
which binds to the extracellular segment of the HER2/neu
(erbB2) receptor [4]. Despite the controversy for public
health funding in UK, it was approved by the NICE in June
2006 (following its European licence) and its initiation is
based upon identification of HER-2 over expression. The
combination of Trastuzumab with chemotherapy has
been shown to increase both survival and response rate, in
comparison to Trastuzumab alone. Recent trials have
shown 50% reduction of the relapse risk in the adjuvant
setting (after the initial diagnosis) for one year [5].
In our patient the ocular lesion was diagnosed relatively
early, and she underwent a combined treatment of chem-
otherapy and Trastuzumab to increase the response rate.
Nine months following therapy her condition was stable
and her vision was preserved.
Conclusion
Though further follow up is essential, this case report
highlights the significant impact of monoclonal antibody
therapy, as an alternative to external beam radiotherapy in
patients with ocular metastasis from HER2 (+) breast can-
cer.
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